advantage in metastatic breast cancer by combining chemotherapy with a targeted agent. This trial and others also revealed that the benefit of trastuzumab is limited to women with breast cancers strongly overexpressing ErbB2 (immunohistochemistry (IHC) 2+ or 3+; fluorescent in situ hybridization (FISH)+). On the other hand, researchers and clinicians had to learn about the cardiotoxicity of the antibody, especially in women treated with anthracyclines or presenting with cardiovascular comorbidities. Having established the principal efficacy of the trastuzumabbased therapy, newer studies addressed the issue of optimizing the anti-ErbB2 therapy. In a randomized phase II trial, Marty et al.
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advantage in metastatic breast cancer by combining chemotherapy with a targeted agent. This trial and others also revealed that the benefit of trastuzumab is limited to women with breast cancers strongly overexpressing ErbB2 (immunohistochemistry (IHC) 2+ or 3+; fluorescent in situ hybridization (FISH)+). On the other hand, researchers and clinicians had to learn about the cardiotoxicity of the antibody, especially in women treated with anthracyclines or presenting with cardiovascular comorbidities. Having established the principal efficacy of the trastuzumabbased therapy, newer studies addressed the issue of optimizing the anti-ErbB2 therapy. In a randomized phase II trial, Marty et al. [8] demonstrated a significant survival benefit for patients receiving a combination therapy with docetaxel and trastuzumab, compared to women who were treated with docetaxel only and received trastuzumab after progression (p = 0.0325). This result underlines the basic principle in antitumor therapy: to use the most effective drugs as early in the course of the disease as possible. Apart from anthracyclines and taxanes, many other combinations of chemotherapy and trastuzumab have been clinically tested, based on preclinical evidence of synergistic or additive activity, when combining the monoclonal antibody with cytotoxics such as vinorelbine or cisplatin [8] . Optimal duration of trastuzumab therapy remains an unanswered question. It is widespread clinical practice to continue the monoclonal antibody with second-line chemotherapy after progression, although the benefit of this strategy has never been established in a prospective randomized clinical trial. Based on a treatment extension trial (H0659g) by Tripathy et al. [9] and experience from retrospective analyses, the safety of giving trastuzumab beyond progression can be assumed [9] [10] [11] . The trial Treatment Beyond Progression, initiated by the German Breast Group, which compares capecitabine as monotherapy versus capecitabine plus trastuzumab continuation in patients with metastatic ErbB2-overexpressing breast cancer,
Identification of ErbB2 (HER2) as Treatment Target
The traditional view of breast cancer as a single-tumor entity has been challenged in recent years. Today, breast cancer is considered a heterogeneous group of different carcinomas, one of them being the ErbB2-overexpressing breast tumor. The adverse prognosis of women with ErbB2-overexpressing breast cancer and the correlation of survival and relapse rates with the number of ErbB2 gene copies were described 20 years ago by Slamon et al. [1] . The monoclonal antibody trastuzumab was the first agent targeting the ErbB2 signaling pathway and received FDA approval in 1998. The molecular characterization of ErbB2-overexpressing breast cancer and the development of trastuzumab were made possible by the identification of a new receptor with extensive homology to the epidermal growth factor receptor (EGFR), which was, therefore, named Human EGFR-Related Receptor (HER2) [2] . It could also be demonstrated that HER2 shares the same gene locus as the neu oncogene identified in tumors of the rat [2-5].
Development of Anti-ErbB2 Therapy
Trastuzumab was initially investigated as a single agent in the therapy of metastatic breast cancer, and was shown to be generally safe and to produce response rates in the range of 12-35% [6] . These first results were somewhat disappointing, but they probably reflect the fact that cancer is not a monogenic disease linked to only one molecular alteration. Therefore, multimodality treatment approaches and multi-targeted agents are needed for better treatment outcome. The combination of trastuzumab with anthracycline/cyclophosphamide or paclitaxel provided additional benefit with higher rates of response and survival. The pivotal trial by Slamon et al. [7] showed for the first time a significant survival who progressed during trastuzumab treatment, did not reach its recruitment goal and was terminated prematurely [12] .
Potential Drawbacks of Single-Targeted Therapy
Despite the high activity of combination therapies with trastuzumab and cytotoxic drugs, a substantial proportion of patients with ErbB2-overexpressing breast cancer will not benefit. In the first-line setting, only 50-60% of patients will respond to regimens with trastuzumab and a taxane (table 1) [6, 7] . The inhibition of only one target of the ErbB family does not appear to be sufficient, in part because of the redundancy in ErbB-mediated intracellular downstream signaling. In addition, response duration in responders to trastuzumab plus a taxane or vinorelbine is limited (table 2): The majority of patients will progress within a year after therapy initiation [6, 7, 13] . Long-lasting control of the metastatic disease or even cure is not within reach. With better control of the systemic disease and longer survival times, the increasing incidence of central nervous system (CNS) disease also represents a growing challenge which cannot be addressed with trastuzumab. It is evident that there still is a significant unmet medical need for trastuzumab-pretreated patients with ErbB2-overexpressing breast tumors. Novel anti-ErbB2 therapies, such as the ErbB tyrosine kinase inhibitors which act through different mechanisms, could provide additional benefit in treating women with this type of breast cancer.
From Single-Target to Multi-Target Agents
In the early development of small molecules inhibiting receptor tyrosine kinases, the effort was focused on creating very selective agents targeting only one specific molecule. Examples are erlotinib and gefitinib which were designed to block the tyrosine kinase of EGFR, thereby interfering with the signal transduction initiated by this receptor. But there is growing evidence that these single-targeted inhibitors are less specific than initially thought and presumably block several receptor kinases. As the different signaling pathways form a complex and partially overlapping intracellular network, it appears to be more appropriate to develop multi-targeted tyrosine kinase inhibitors which are able to modulate several signal transduction pathways. Examples for these multi-targeted agents are sunitinib, which blocks many different kinases including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors and thereby angiogenesis, tumor cell proliferation, and metastatic properties, and lapatinib which inhibits ErbB1 and ErbB2. Moreover, it was demonstrated in vitro that these drugs are even less specific: For example, sunitinib has been shown to inhibit about 130 kinases. Future anti-cancer therapies should use combinations of several tyrosine kinase inhibitors with different targets, e.g. in the EGFR and VEGFR signaling pathways, in order to maximize the effects against tumor cells with their highly activated signal transduction systems. [14] 1st or 2nd/3rd T + V 5. 
Methods of Measuring ErbB2-Overexpression
Presumably, the clinical application of modern targeted agents can help to individualize the therapy of cancer patients by tailoring treatment to tumors defined by the specific target. This requires the development of methods to identify the molecular target in tumors and biopsies. Besides hormone receptors, ErbB2 has proven its value in predicting clinical sensitivity to a targeted therapy in breast cancer. Routinely, the ErbB2 status of breast cancer patients is assessed by 2 methods: By IHC, the expression of the receptor protein in the cell membrane is estimated by a score ranging from 0 to 3. An IHC value of 3+ represents ErbB2 overexpression and has been defined as an indication for the initiation of an anti-ErbB2 therapy. By contrast, an IHC score of 2+ is more difficult to interpret and needs validation by FISH, a method which quantifies gene amplification. There has been much discussion about which method being the optimal one for treatment decisions. Advantages of the IHC are its broad availability in nearly every pathological lab, the simplicity of the method and low costs. In comparison to FISH data, 8-22% of measurements have been called false negative, and up to 40% false positive [14] . The reproducibility of local IHC3+ test results by central testing normally lies in the range of 76-84% with values close to FISH data if standardized test systems and the same tissue block have been used for both methods (81.6% in IHC versus 88.6% for FISH) [15] . By contrast, FISH has a high reliability and the results are more reproducible so that FISH was claimed to be the gold standard in ErbB2 testing [16] . Disadvantages of this method are high costs and the availability in specialized labs only. In general, IHC 3+ tumors also stain positive in the FISH analysis. fig. 1 ). It has to be kept in mind that FISH assays can also give intermediate results which were defined by ASCO and CAP as HER2/CEP17 ratios ranging from 1.8 to 2.2. Nevertheless, such specimens can show a strong IHC3+ expression, probably due to polysomy 17 which is observed in about 8% of all breast cancer specimens [19, 20] . At least some of these cases are responders to trastuzumab [21] . Therefore, FISH-negative test results with polysomy 17 (FISH ratio < 1.8 or gene copy number < 4) have to be validated by IHC. By application of the new expert consensus, a huge reduction in IHC false positive results and a reduction in FISH false negative test results can be assumed. To achieve this goal, the ASCO and CAP expert panel recommends i) validation of laboratory assays or modifications; ii) use of standardized operating procedures; iii) compliance with new testing criteria; iv) stringent laboratory accreditation standards; and v) proficiency testing and competency assessment [18] .
A new technique to improve reproducibility of the test results and to increase response prediction is chromogenic in situ hybridization (CISH) which is currently in the process of FDA approval [22] . CISH is a colorimetric modification of the FISH assay that will probably replace FISH in the near future because of a higher accuracy of results. Fig. 1 . ASCO/CAP recommendations for ErbB2 testing, adapted from [18] .
